Advertisement

Clinical Drug Investigation

, Volume 37, Issue 7, pp 635–646 | Cite as

Efficacy of Interferon-Free Therapies for Chronic Hepatitis C: A Systematic Review of All Randomized Clinical Trials

  • Vinicius L. Ferreira
  • Fernanda S. Tonin
  • Nayara A. Assis Jarek
  • Yohanna Ramires
  • Roberto Pontarolo
Systematic Review

Abstract

Background and Objectives

Second-generation direct-acting antivirals (DAAs) have recently arisen as more effective and safer treatments for chronic hepatitis C. These drugs can be combined into treatments without interferon (IFN), and are therefore called IFN-free therapies.

Objective

The objective of this study systematic review was to evaluate the efficacy of IFN-free therapies for the treatment of chronic hepatitis C, and thus increase the clinical evidence for these therapies.

Methods

A systematic review was conducted in accordance with Cochrane Collaboration recommendations. A search was performed in six different electronic databases using ‘clinical trials’, ‘hepatitis C’ and ‘interferon-free’ as the main descriptors, and studies that conformed to the inclusion criteria had their data extracted, including study information, baseline characteristics, and efficacy outcomes (sustained virologic response, rapid virologic response, and virologic failure).

Results

Sixty-four randomized clinical trials including 15 different therapies were included in a total of 15,731 patients infected with the hepatitis C virus, mostly with genotype 1, and mainly treated for 12 or 24 weeks. The sustained virologic response rate after 12 weeks of treatment was approximately 89%, while the virologic failure rate was below 5%.

Conclusions

Second-generation DAAs presented several advantages: virologic response values higher than the average achieved by previous IFN-based therapies, reduced treatment duration, and the possibility of different combinations of therapies to meet patient needs. Thus, IFN-free therapies appear to be valuable alternatives for the treatment of chronic hepatitis C.

Keywords

Chronic Hepatitis Sustained Virological Response Virologic Failure Sustained Virologic Response Rate Telaprevir 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Compliance with Ethical Standards

Funding

No funding was received for this work.

Conflict of interest

Vinicius L. Ferreira, Fernanda S. Tonin, Nayara A. Assis Jarek, Yohanna Ramires and and Roberto Pontarolo declare no relevant conflicts of interest.

Supplementary material

40261_2017_521_MOESM1_ESM.docx (16 kb)
Supplementary material 1 (DOCX 16 kb)

References

  1. 1.
    World Health Organization. Guidelines for the screening, care and treatment of persons with hepatitis C infection Geneva: World Health Organization; 2014.Google Scholar
  2. 2.
    Sulkowski MS, Cooper C, Hunyady B, Jia J, Ogurtsov P, Peck-Radosavljevic M, et al. Management of adverse effects of Peg-IFN and ribavirin therapy for hepatitis C. Nat Rev Gastroenterol Hepatol. 2011;8:212–23.CrossRefPubMedGoogle Scholar
  3. 3.
    European Association of the Study of the Liver. EASL clinical practice guidelines: management of hepatitis C virus infection. J Hepatol. 2011;55:245–64.CrossRefGoogle Scholar
  4. 4.
    Zeuzem S, Hezode C, Bronowicki JP, Loustaud-Ratti V, Gea F, Buti M, et al. Daclatasvir plus simeprevir with or without ribavirin for the treatment of chronic hepatitis C virus genotype 1 infection. J Hepatol. 2015;64(292):300.Google Scholar
  5. 5.
    American Association for the Study of Liver Diseases. Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus. Hepatology. 2015;62:932–54.CrossRefGoogle Scholar
  6. 6.
    European Association of the Study of the Liver. EASL recommendations on treatment of hepatitis C 2015. J Hepatol. 2015;63:199–236.CrossRefGoogle Scholar
  7. 7.
    Molina JM, Orkin C, Iser DM, Zamora FX, Nelson M, Stephan C, et al. Sofosbuvir plus ribavirin for treatment of hepatitis C virus in patients co-infected with HIV (PHOTON-2): a multicentre, open-label, non-randomised, phase 3 study. Lancet. 2015;385:1098–106.CrossRefPubMedGoogle Scholar
  8. 8.
    Higgins JPT, Green S. Cochrane handbook for systematic reviews of interventions version 5.1.0: Cochrane Collaboration; 2011.Google Scholar
  9. 9.
    Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JPA, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ. 2009;339.Google Scholar
  10. 10.
    Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials. 1996;17:1–12.CrossRefPubMedGoogle Scholar
  11. 11.
    Andreone P, Colombo MG, Enejosa JV, Koksal I, Ferenci P, Maieron A, et al. ABT-450, ritonavir, ombitasvir, and dasabuvir achieves 97% and 100% sustained virologic response with or without ribavirin in treatment-experienced patients with HCV genotype 1b infection. Gastroenterology. 2014;147(2):359.CrossRefPubMedGoogle Scholar
  12. 12.
    Chayama K, Notsumata K, Kurosaki M, Sato K, Rodrigues L Jr, Setze C, et al. Randomized trial of interferon- and ribavirin-free ombitasvir/paritaprevir/ritonavir in treatment-experienced hepatitis C virus-infected patients. Hepatology. 2015;61:1523–32.CrossRefPubMedGoogle Scholar
  13. 13.
    Dore GJ, Conway B, Luo Y, Janczewska E, Knysz B, Liu Y, et al. Efficacy and safety of ombitasvir/paritaprevir/r and dasabuvir compared to IFN-containing regimens in genotype 1 HCV patients: the MALACHITE-I/II trials. J Hepatol. 2016;64:19–28.CrossRefPubMedGoogle Scholar
  14. 14.
    Feld JJ, Kowdley KV, Coakley E, Sigal S, Nelson DR, Crawford D, et al. Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med. 2014;370:1594–603.CrossRefPubMedGoogle Scholar
  15. 15.
    Ferenci P, Bernstein D, Lalezari J, Cohen D, Luo Y, Cooper C, et al. ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV. N Engl J Med. 2014;370:1983–92.CrossRefPubMedGoogle Scholar
  16. 16.
    Hézode C, Asselah T, Reddy KR, Hassanein T, Berenguer M, Fleischer-Stepniewska K, et al. Ombitasvir plus paritaprevir plus ritonavir with or without ribavirin in treatment-naive and treatment-experienced patients with genotype 4 chronic hepatitis C virus infection (PEARL-I): a randomised, open-label trial. Lancet. 2015;385:2502–9.CrossRefPubMedGoogle Scholar
  17. 17.
    Kumada H, Chayama K, Rodrigues L Jr, Suzuki F, Ikeda K, Toyoda H, et al. Randomized phase 3 trial of ombitasvir/paritaprevir/ritonavir for hepatitis C virus genotype 1b-infected Japanese patients with or without cirrhosis. Hepatology. 2015;62:1037–46.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Poordad F, Hezode C, Trinh R, Kowdley KV, Zeuzem S, Agarwal K, et al. ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. N Engl J Med. 2014;370:1973–82.CrossRefPubMedGoogle Scholar
  19. 19.
    Zeuzem S, Jacobson IM, Baykal T, Marinho RT, Poordad F, Bourlière M, et al. Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med. 2014;370:1604–14.CrossRefPubMedGoogle Scholar
  20. 20.
    Kowdley KV, Lawitz E, Poordad F, Cohen DE, Nelson DR, Zeuzem S, et al. Phase 2b trial of interferon-free therapy for hepatitis C virus genotype 1. N Engl J Med. 2014;370:222–32.CrossRefPubMedGoogle Scholar
  21. 21.
    Jacobson IM, Gordon SC, Kowdley KV, Yoshida EM, Rodriguez-Torres M, Sulkowski MS, et al. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med. 2013;368:1867–77.CrossRefPubMedGoogle Scholar
  22. 22.
    Lawitz E, Sulkowski MS, Ghalib R, Rodriguez-Torres M, Younossi ZM, Corregidor A, et al. Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study. Lancet. 2014;384:1756–65.CrossRefPubMedGoogle Scholar
  23. 23.
    Gane EJ, Stedman CA, Hyland RH, Ding X, Svarovskaia E, Symonds WT, et al. Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C. N Engl J Med. 2013;368:34–44.CrossRefPubMedGoogle Scholar
  24. 24.
    Osinusi A, Meissner EG, Lee YJ, Bon D, Heytens L, Nelson A, et al. Sofosbuvir and ribavirin for hepatitis C genotype 1 in patients with unfavorable treatment characteristics: a randomized clinical trial. JAMA. 2013;310:804–11.CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Zeuzem S, Dusheiko GM, Salupere R, Mangia A, Flisiak R, Hyland RH, et al. Sofosbuvir and ribavirin in HCV genotypes 2 and 3. N Engl J Med. 2014;370:1993–2001.CrossRefPubMedGoogle Scholar
  26. 26.
    Foster GR, Pianko S, Brown A, Forton D, Nahass RG, George J, et al. Efficacy of sofosbuvir plus ribavirin with or without peginterferon-alfa in patients with HCV genotype 3 infection and treatment-experienced patients with cirrhosis and HCV genotype 2 infection. Gastroenterology. 2015;149:1462–70.CrossRefPubMedGoogle Scholar
  27. 27.
    Kwo P, Gitlin N, Nahass R, Bernstein D, Rojter S, Schiff E, et al. A phase 3, randomised, open-label study to evaluate the efficacy and safety of 8 and 12 weeks of simeprevir (SMV) plus sofosbuvir (sof) in treatment-naive and -experienced patients with chronic HCV genotype 1 infection without cirrhosis: Optimist-1. J Hepatol. 2015;62:S270-S.Google Scholar
  28. 28.
    Curry MP, O’Leary JG, Bzowej N, Muir AJ, Korenblat KM, Fenkel JM, et al. Sofosbuvir and velpatasvir for HCV in patients with decompensated cirrhosis. N Engl J Med. 2015;373:2618–28.CrossRefPubMedGoogle Scholar
  29. 29.
    Feld JJ, Jacobson IM, Hezode C, Asselah T, Ruane PJ, Gruener N, et al. Sofosbuvir and velpatasvir for HCV genotype 1, 2, 4, 5, and 6 infection. N Engl J Med. 2015;373:2599–607.CrossRefPubMedGoogle Scholar
  30. 30.
    Zeuzem S, Dufour JF, Buti M, Soriano V, Buynak RJ, Mantry P, et al. Interferon-free treatment of chronic hepatitis C with faldaprevir, deleobuvir and ribavirin: SOUND-C3, a Phase 2b study. Liver Int. 2015;35:417–21.CrossRefPubMedGoogle Scholar
  31. 31.
    Doss W, Shiha G, Hassany M, Soliman R, Fouad R, Khairy M, et al. Sofosbuvir plus ribavirin for treating Egyptian patients with hepatitis C genotype 4. J Hepatol. 2015;63:581–5.CrossRefPubMedGoogle Scholar
  32. 32.
    Foster GR, Afdhal N, Roberts SK, Bräu N, Gane EJ, Pianko S, et al. Sofosbuvir and velpatasvir for HCV genotype 2 and 3 infection. N Engl J Med. 2015;373:2608–17.CrossRefPubMedGoogle Scholar
  33. 33.
    Ruane PJ, Ain D, Stryker R, Meshrekey R, Soliman M, Wolfe PR, et al. Sofosbuvir plus ribavirin for the treatment of chronic genotype 4 hepatitis C virus infection in patients of Egyptian ancestry. J Hepatol. 2015;62:1040–6.CrossRefPubMedGoogle Scholar
  34. 34.
    Shihai G, Esmat G, Hassany M, Fouad R, Samir W, Hammad R, et al. Sofosbuvir plus ribavirin an interferon free regimen in the treatment of Egyptian patients with chronic genotype 4 HCV infection. Hepatol Int. 2015;9(1 Suppl. 1):S54.Google Scholar
  35. 35.
    Lalezari JP, Nelson DR, Hyland RH, Lin M, Rossi SJ, Symonds WT, et al. Once daily sofosbuvir plus ribavirin for 12 and 24 weeks in treatment-naive patients with HCV infection: the Quantum Study. J Hepatol. 2013;58:S346.CrossRefGoogle Scholar
  36. 36.
    Everson GT, Sims KD, Rodriguez-Torres M, Hezode C, Lawitz E, Bourliere M, et al. Efficacy of an interferon- and ribavirin-free regimen of daclatasvir, asunaprevir, and BMS-791325 in treatment-naive patients with HCV genotype 1 infection. Gastroenterology. 2014;146:420–9.CrossRefPubMedGoogle Scholar
  37. 37.
    Lok AS, Gardiner DF, Hezode C, Lawitz EJ, Bourliere M, Everson GT, et al. Randomized trial of daclatasvir and asunaprevir with or without PegIFN/RBV for hepatitis C virus genotype 1 null responders. J Hepatol. 2014;60:490–9.CrossRefPubMedGoogle Scholar
  38. 38.
    Manns M, Pol S, Jacobson IM. All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort study. Lancet. 2014;384:1576.CrossRefGoogle Scholar
  39. 39.
    Muir AJ, Poordad F, Lalezari J, Everson G, Dore GJ, Herring R, et al. Daclatasvir in combination with asunaprevir and beclabuvir for hepatitis C virus genotype 1 infection with compensated cirrhosis. JAMA. 2015;313:1736–44.CrossRefPubMedGoogle Scholar
  40. 40.
    Hassanein T, Sims KD, Bennett M, Gitlin N, Lawitz E, Nguyen T, et al. A randomized trial of daclatasvir in combination with asunaprevir and beclabuvir in patients with chronic hepatitis C virus genotype 4 infection. J Hepatol. 2015;62:1204–18.CrossRefPubMedGoogle Scholar
  41. 41.
    Sulkowski MS, Gardiner DF, Rodriguez-Torres M, Reddy KR, Hassanein T, Jacobson I, et al. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med. 2014;370:211–21.CrossRefPubMedGoogle Scholar
  42. 42.
    Zeuzem S, Hezode C, Bronowicki JP, Loustaud-Ratti V, Gea F, Buti M, et al. Daclatasvir plus simeprevir with or without ribavirin for the treatment of chronic hepatitis C virus genotype 1 infection. J Hepatol. 2016;64:292–300.CrossRefPubMedGoogle Scholar
  43. 43.
    Afdhal N, Reddy KR, Nelson DR, Lawitz E, Gordon SC, Schiff E, et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med. 2014;370:1483–93.CrossRefPubMedGoogle Scholar
  44. 44.
    Afdhal N, Zeuzem S, Kwo P, Chojkier M, Gitlin N, Puoti M, et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med. 2014;370:1889–98.CrossRefPubMedGoogle Scholar
  45. 45.
    Kowdley KV, Gordon SC, Reddy KR, Rossaro L, Bernstein DE, Lawitz E, et al. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med. 2014;370:1879–88.CrossRefPubMedGoogle Scholar
  46. 46.
    Gane EJ, Stedman CA, Hyland RH, Ding X, Svarovskaia E, Subramanian GM, et al. Efficacy of nucleotide polymerase inhibitor sofosbuvir plus the NS5A inhibitor ledipasvir or the NS5B non-nucleoside inhibitor GS-9669 against HCV genotype 1 infection. Gastroenterology. 2014;146(736–43):e1.Google Scholar
  47. 47.
    Lawitz E, Poordad FF, Pang PS, Hyland RH, Ding X, Mo H, et al. Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial. Lancet. 2014;383:515–23.CrossRefPubMedGoogle Scholar
  48. 48.
    Bourliere M, Bronowicki JP, de Ledinghen V, Hezode C, Zoulim F, Mathurin P, et al. Ledipasvir-sofosbuvir with or without ribavirin to treat patients with HCV genotype 1 infection and cirrhosis non-responsive to previous protease-inhibitor therapy: a randomised, double-blind, phase 2 trial (SIRIUS). Lancet Infect Dis. 2015;15:397–404.CrossRefPubMedGoogle Scholar
  49. 49.
    Mizokami M, Yokosuka O, Takehara T, Sakamoto N, Korenaga M, Mochizuki H, et al. Ledipasvir and sofosbuvir fixed-dose combination with and without ribavirin for 12 weeks in treatment-naive and previously treated Japanese patients with genotype 1 hepatitis C: an open-label, randomised, phase 3 trial. Lancet Infect Dis. 2015;15:645–53.CrossRefPubMedGoogle Scholar
  50. 50.
    Charlton M, Everson GT, Flamm SL, Kumar P, Landis C, Brown RS Jr, et al. Ledipasvir and sofosbuvir plus ribavirin for treatment of HCV infection in patients with advanced liver disease. Gastroenterology. 2015;149:649–59.CrossRefPubMedGoogle Scholar
  51. 51.
    Feld JJ, Jacobson IM, Jensen DM, Foster GR, Pol S, Tam E, et al. Randomized study of danoprevir/ritonavir-based therapy for HCV genotype 1 patients with prior partial or null responses to peginterferon/ribavirin. J Hepatol. 2015;62:294–302.CrossRefPubMedGoogle Scholar
  52. 52.
    Wyles DL, Rodriguez-Torres M, Lawitz E, Shiffman ML, Pol S, Herring RW, et al. All-oral combination of ledipasvir, vedroprevir, tegobuvir, and ribavirin in treatment-naive patients with genotype 1 HCV infection. Hepatology. 2014;60:56–64.CrossRefPubMedGoogle Scholar
  53. 53.
    Gane EJ, Pockros PJ, Zeuzem S, Marcellin P, Shikhman A, Bernaards C, et al. Mericitabine and ritonavir-boosted danoprevir with or without ribavirin in treatment-naive HCV genotype 1 patients: INFORM-SVR study. Liver Int. 2015;35:79–89.CrossRefPubMedGoogle Scholar
  54. 54.
    Lawitz E, Gane E, Pearlman B, Tam E, Ghesquiere W, Guyader D, et al. Efficacy and safety of 12 weeks versus 18 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin for hepatitis C virus genotype 1 infection in previously untreated patients with cirrhosis and patients with previous null response with or without cirrhosis (C-WORTHY): a randomised, open-label phase 2 trial. Lancet. 2015;385:1075–86.CrossRefPubMedGoogle Scholar
  55. 55.
    Sulkowski M, Hezode C, Gerstoft J, Vierling JM, Mallolas J, Pol S, et al. Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C virus genotype 1 mono-infection and HIV/hepatitis C virus co-infection (C-WORTHY): a randomised, open-label phase 2 trial. Lancet. 2015;385:1087–97.CrossRefPubMedGoogle Scholar
  56. 56.
    Zeuzem S, Soriano V, Asselah T, Bronowicki JP, Lohse AW, Mullhaupt B, et al. Faldaprevir and deleobuvir for HCV genotype 1 infection. N Engl J Med. 2013;369:630–9.CrossRefPubMedGoogle Scholar
  57. 57.
    Manns M, Samuel D, Gane EJ, Mutimer D, McCaughan G, Buti M, et al. Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trial. Lancet Infect Dis. 2016;16:685–97.CrossRefPubMedGoogle Scholar
  58. 58.
    Gane E, Ben Ari Z, Mollison L, Zuckerman E, Bruck R, Baruch Y, et al. Efficacy and safety of grazoprevir + ribavirin for 12 or 24 weeks in treatment-naive patients with hepatitis C virus genotype 1 infection. J Viral Hepat. 2016;23:789–97.CrossRefPubMedGoogle Scholar
  59. 59.
    Kumada H, Suzuki F, Suzuki Y, Toyota J, Karino Y, Chayama K, et al. Randomized comparison of daclatasvir + asunaprevir versus telaprevir + peginterferon/ribavirin in Japanese hepatitis C virus patients. J Gastroenterol Hepatol. 2016;31:14–22.CrossRefPubMedGoogle Scholar
  60. 60.
    Leroy V, Angus P, Bronowicki JP, Dore GJ, Hezode C, Pianko S, et al. Daclatasvir, sofosbuvir, and ribavirin for hepatitis C virus genotype 3 and advanced liver disease: a randomized phase III study (ALLY-3 +). Hepatology. 2016;63:1430–41.CrossRefPubMedPubMedCentralGoogle Scholar
  61. 61.
    Asselah T, Hezode C, Qaqish RB, ElKhashab M, Hassanein T, Papatheodoridis G, et al. High SVR rates in patients with genotype 4 chronic hepatitis Cinfection and compensated cirrhosis with ombitasvir/paritaprevir/ritonavir co-administered with ribavirin (AGATE-I). J Hepatol. 2016;64(Suppl):S827.Google Scholar
  62. 62.
    Bourgeois S, Van Vlierberghe H, Moreno C, Orlent H, Nevens F, Arasteh K, et al. Efficacy, safety and pharmacokinetics of simeprevir and TMC647055/ritonavir with or without ribavirin and JNJ-56914845 in HCV genotype 1 infection. BMC Gastroenterol. 2017;17:26.CrossRefPubMedPubMedCentralGoogle Scholar
  63. 63.
    Colombo M, Aghemo A, Liu L, Hyland R, Yun C, Brainard D, et al. Ledipasvir/sofosbuvir for 12 or 24 weeks is safe and effective in kidney transplant recipients with chronic genotype 1 or 4 hcv infection. J Hepatol. 2016;64:S183.CrossRefGoogle Scholar
  64. 64.
    George J, Burnevich EZ, Sheen IS, Heo J, Van KN, Tanwandee T, et al. Efficacy and safety of elbasvir/grazoprevir in treatment-naive subjects with chronic HCV GT 1, GT 4 and GT 6 infection (C-CORAL): a phase III randomized multinational clinical trial. Hepatology. 2016; 64(Suppl S1):76.Google Scholar
  65. 65.
    Kumada H, Suzuki Y, Karino Y, Chayama K, Kawada N, Okanoue T, et al. The combination of elbasvir and grazoprevir for the treatment of chronic HCV infection in Japanese patients: a randomized phase II/III study. J Gastroenterol. 2017;52(4):520–33.CrossRefPubMedGoogle Scholar
  66. 66.
    Kwo P, Gane EJ, Peng CY, Pearlman B, Vierling JM, Serfaty L, et al. Effectiveness of elbasvir and grazoprevir combination, with or without ribavirin, for treatment-experienced patients with chronic hepatitis C infection. Gastroenterology. 2017;152(164–175):e4.Google Scholar
  67. 67.
    Shah SR, Chowdhury A, Mehta R, Kapoor D, Duseja A, Koshy A, et al. Sofosbuvir plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 or 3 infection in India. J Viral Hepatol. 2017. doi: 10.1111/jvh.12654.
  68. 68.
    Sperl J, Horvath G, Halota W, Ruiz-Tapiador JA, Streinu-Cercel A, Jancoriene L, et al. Efficacy and safety of elbasvir/grazoprevir and sofosbuvir/pegylated interferon/ribavirin: A phase III randomized controlled trial. J Hepatol. 2016;65:1112–9.CrossRefPubMedGoogle Scholar
  69. 69.
    Suzuki F, Karino Y, Chayama K, Kawada N, Okanoue T, Itoh Y, et al. Final results from phase 3 portion in phase 2/3 study of elbasvir/grazoprevir in hepatitis C genotype 1 infected Japanese patients. Hepatology. 2016;64:851(S1).Google Scholar
  70. 70.
    Waked I, Shiha G, Qaqish RB, Esmat G, Yosry A, Hassany M, et al. Ombitasvir, paritaprevir, and ritonavir plus ribavirin for chronic hepatitis C virus genotype 4 infection in Egyptian patients with or without compensated cirrhosis (AGATE-II): a multicentre, phase 3, partly randomised open-label trial. Lancet Gastroenterol Hepatol. 2017;1:36–44.CrossRefGoogle Scholar
  71. 71.
    Toyota J, Karino Y, Suzuki F, Ikeda F, Ido A, Tanaka K, et al. Daclatasvir/asunaprevir/beclabuvir fixed-dose combination in Japanese patients with HCV genotype 1 infection. J Gastroenterol. 2017;52:385–95.CrossRefPubMedGoogle Scholar
  72. 72.
    Pearlman BL, Traub N. Sustained virologic response to antiviral therapy for chronic hepatitis C virus infection: a cure and so much more. Clin Infect Dis. 2011;52:889–900.CrossRefPubMedGoogle Scholar
  73. 73.
    Camma C, Petta S, Enea M, Bruno R, Bronte F, Capursi V, et al. Cost-effectiveness of boceprevir or telaprevir for untreated patients with genotype 1 chronic hepatitis C. Hepatology. 2012;56:850–60.CrossRefPubMedGoogle Scholar
  74. 74.
    Shahid I, ALMalki WH, Hafeez MH, Hassan S. Hepatitis C virus infection treatment: an era of game changer direct acting antivirals and novel treatment strategies. Crit Rev Microbiol. 2016;42(4):535–47.PubMedGoogle Scholar
  75. 75.
    Simin M, Brok J, Stimac D, Gluud C, Gluud LL. Cochrane systematic review: pegylated interferon plus ribavirin vs. interferon plus ribavirin for chronic hepatitis C. Aliment Pharmacol Ther. 2007;25(10):1153–62.CrossRefPubMedGoogle Scholar
  76. 76.
    Awad T, Thorlund K, Hauser G, Stimac D, Mabrouk M, Gluud C. Peginterferon alpha-2a is associated with higher sustained virological response than peginterferon alfa-2b in chronic hepatitis C: systematic review of randomized trials. Hepatology. 2010;51(4):1176–84.CrossRefPubMedGoogle Scholar
  77. 77.
    Fried MW, Hadziyannis SJ, Shiffman ML, Messinger D, Zeuzem S. Rapid virological response is the most important predictor of sustained virological response across genotypes in patients with chronic hepatitis C virus infection. J Hepatol. 2011;55:69–75.CrossRefPubMedGoogle Scholar
  78. 78.
    Ferreira VL, Assis Jarek NA, Tonin FS, Borba HH, Wiens A, Muzzillo DA, et al. Ledipasvir/sofosbuvir with or without ribavirin for the treatment of chronic hepatitis C genotype 1: a pairwise meta-analysis. J Gastroenterol Hepatol. 2017;32:749–55.CrossRefPubMedGoogle Scholar
  79. 79.
    Tao T, Jiang X, Chen Y, Song Y. Efficacy and safety of ledipasvir/sofosbuvir with and without ribavirin in patients with chronic hepatitis C virus genotype 1 infection: a meta-analysis. Int J Infect Dis. 2017;55:56–71.CrossRefPubMedGoogle Scholar
  80. 80.
    Ferreira VL, Assis Jarek NA, Tonin FS, Borba HH, Wiens A, Pontarolo R. Safety of interferon-free therapies for chronic hepatitis C: a network meta-analysis. J Clin Pharm Ther. 2016;41:478–85.CrossRefPubMedGoogle Scholar
  81. 81.
    Tong MJ, Chang PW, Huynh TT, Rosinski AA, Tong LT. Adverse events associated with ribavirin in sofosbuvir-based therapies for patients with chronic hepatitis C: a community practice experience. J Dig Dis. 2016;17:113–21.CrossRefPubMedGoogle Scholar
  82. 82.
    Berden FA, Aaldering BR, Groenewoud H, IntHout J, Kievit W, Drenth JP. Identification of the best direct-acting antiviral regimen for patients with hepatitis C virus genotype 3 infection: a systematic review and network meta-analysis. Clin Gastroenterol Hepatol. 2017;15:349–59.CrossRefPubMedGoogle Scholar
  83. 83.
    Menon RM, Badri PS, Wang T, Polepally AR, Zha J, Khatri A, et al. Drug-drug interaction profile of the all-oral anti-hepatitis C virus regimen of paritaprevir/ritonavir, ombitasvir, and dasabuvir. J Hepatol. 2015;63:20–9.CrossRefPubMedGoogle Scholar
  84. 84.
    El-Sherif O, Back D. Drug interactions of hepatitis C direct-acting antivirals in the HIV-infected person. Curr HIV/AIDS Rep. 2015;12:336–43.CrossRefPubMedGoogle Scholar
  85. 85.
    Talavera Pons S, Boyer A, Lamblin G, Chennell P, Chatenet FT, Nicolas C, et al. Managing drug-drug interactions with new direct-acting antiviral agents in chronic hepatitis C. Br J Clin Pharmacol. 2017;83:269–93.CrossRefPubMedGoogle Scholar
  86. 86.
    Yau AH, Yoshida EM. Hepatitis C drugs: the end of the pegylated interferon era and the emergence of all-oral interferon-free antiviral regimens: a concise review. Can J Gastroenterol Hepatol. 2014;28:445–51.CrossRefPubMedPubMedCentralGoogle Scholar
  87. 87.
    Gutierrez JA, Lawitz EJ, Poordad F. Interferon-free, direct-acting antiviral therapy for chronic hepatitis C. J Viral Hepat. 2015;22(861):70.Google Scholar

Copyright information

© Springer International Publishing Switzerland 2017

Authors and Affiliations

  • Vinicius L. Ferreira
    • 1
  • Fernanda S. Tonin
    • 1
  • Nayara A. Assis Jarek
    • 1
  • Yohanna Ramires
    • 1
  • Roberto Pontarolo
    • 1
  1. 1.Department of PharmacyPharmaceutical Sciences Postgraduate Program, Universidade Federal do ParanáCuritibaBrazil

Personalised recommendations